NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Droid,

Fact ✅️: NWBO has given us plenty to care about. You’re just spreading rumors about the company and distorting the invaluable work the leadership have done and continue to do.

We care about the first commercial license, additional commercial licenses, and we care about a cancer immunotherapy market that will exceed hundreds of billions globally…

The leadership have given us a lot to care about beyond the current OTC price, such as a patent-fortified novel cell-based technology that was peer reviewed, valuable manufacturing technology leading to BLA, the MIA that was already awarded, the MAA that is under review today, and ongoing combo trials…

For example, consider the Roswell Park deal that the leadership achieved for NWBO—perhaps you are unaware of its significance in relation to a rapidly expanding PD-1 / immunotherapy market that is forecast to exceed hundreds of billions globally. Let me help direct you to some reliable sources on the topic of emerging breakthroughs in cell-based immunotherapy. Who are examples of reliable sources?

☑️ The U.S. DoD BCRP
☑️ The U.S. NIH NCI
☑️ Roswell Park
☑️ JCI
☑️ Nature Communications







https://cdmrp.health.mil/bcrp/pbks/2024BCRPProgramBook.pdf

https://clinicaltrials.gov/study/NCT04348747

June 2024

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

“The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumour microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.

The DC based therapies include versions with tumour antigens loaded into the DCs and versions for intra-tumoural administration without pre-loading of antigens. Phase 2 trials involving the licensed technologies for two different cancers opened for enrollment earlier this year and are currently under way, and a third phase 2 trial for a third cancer is pending. The trials are fully funded by grant funding and are being conducted as investigator led trials. The company does not anticipate having to provide any funding or undertake any operational role for these trials.

As previously reported, over time the company has been quietly in-licensing various technologies and IP from various institutions and entities which it believes can be valuable in building a leading franchise in dendritic cell therapies.

The portfolio in-licensed from Roswell Park is complementary to, and builds upon, a portfolio which the company exclusively licensed from another institution last year. Together, the two portfolios encompass more than 20 years of work by one of the foremost groups of dendritic cell experts, led by Dr. Kalinski.

The portfolio in-licensed last year includes the foundational technologies and IP, and positive early-stage clinical trial results, developed by the Kalinski group over 17 years before coming to Roswell. The portfolio in-licensed now includes the further work during the last 7 years at Roswell. Taken together, the company believes that the two portfolios comprise a whole that is greater than the sum of its parts and offer compelling synergies with the company’s own portfolio. The company plans to collaborate with Dr. Kalinski on the further clinical development of the combined technologies.”

https://www.nature.com/articles/s41467-024-48073-y

https://www.jci.org/articles/view/169314

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456


https://finance.yahoo.com/news/cancer-immunotherapy-market-size-reach-124300574.html/

⭐️ Combo is King! ⭐️